Achieve Life Sciences (ACHV) Other Operating Expenses (2014 - 2026)

Achieve Life Sciences' (ACHV) quarterly Other Operating Expenses came in at $341000.0 in Q1 2026, up 610.42% on a QoQ basis from $48000.0 in Q4 2025.

Analysis

Achieve Life Sciences (ACHV) Other Operating Expenses (2014 - 2026) Analysis & Trends

Achieve Life Sciences (ACHV) has 7 years of Other Operating Expenses data on file, last reported at $341000.0 in Q1 2026.

Quarterly Other Operating Expenses changed N/A year-over-year to $341000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $389000.0 (changed N/A YoY) and the FY2025 annual result came in at $48000.0, changed N/A from the prior year.
Other Operating Expenses grew to $341000.0 in Q1 2026, from $48000.0 in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $341000.0 in Q1 2026 to a low of $48000.0 in Q4 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Achieve Life Sciences	369.90 Mn	369.90 Mn	-

Historic Data

Download Data